Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE‐3 study

Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection

(2022) Xiaoling Li et al.   BRITISH JOURNAL OF PHARMACOLOGY

Mechanisms of action of the SGLT2 inhibitor canagliflozin on tubular inflammation and damage: a post‐hoc mediation analysis of the CANVAS trial

(2022) Taha Sen et al.   DIABETES OBESITY & METABOLISM

Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial

(2020) Natalie A. Mordi et al.   CIRCULATION

Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial

(2020) Megumi Oshima et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes

(2019) Y. Lytvyn et al.   DIABETES & METABOLISM

Aldosterone induces albuminuria via matrix metalloproteinase–dependent damage of the endothelial glycocalyx

(2018) Matthew J. Butler et al.   KIDNEY INTERNATIONAL

The glycocalyx—linking albuminuria with renal and cardiovascular disease

(2015) Ton J. Rabelink et al.   Nature Reviews Nephrology

The role of heparanase and the endothelial glycocalyx in the development of proteinuria

(2013) Marjolein Garsen et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION